What is Selank?
A synthetic heptapeptide developed from tuftsin, studied mainly for anxiety; not an FDA-approved anxiety medicine.
Selank in the library · · Human Trials · What are peptides?
0 registered trials · 3 indexed papers · 11 human / 51 animal studies
From the PeptideWhiz library entry. "As described" sections summarize claims made in the sources; they are not PeptideWhiz endorsements.
What it is
Selank is described as a synthetic peptide studied mainly for anxiety. Small human studies have reported improvements but are described as not settling whether it is a dependable long-term treatment. It is described as not an FDA-approved anxiety medicine.
Structure (as described)
- A seven-amino-acid peptide (heptapeptide) developed from tuftsin, a naturally occurring immune-system peptide, by adding three amino acids. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro. That origin explains the interest in nervous-system and immune effects.
- It is described as anxiolytic (intended to reduce anxiety) or nootropic (proposed to improve cognition); those labels describe the questions investigated, not the strength of the evidence.
Evidence (as described)
- Published clinical reports offer preliminary support, mostly from relatively small Russian-language studies; English abstracts describe comparisons with benzodiazepines rather than a large, independently replicated placebo-controlled program.
Peer-reviewed studies (3)
| Paper | Authors | Journal | Year | Type |
|---|---|---|---|---|
| [Optimization of the treatment of anxiety disorders with selank] | Medvedev VE et al. | Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova | 2015 | Randomized Controlled Trial |
| [A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders] | Medvedev VE et al. | Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova | 2014 | Clinical Trial |
| [Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia] | Zozulia AA et al. | Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova | 2008 | Randomized Controlled Trial |
More cited research
- Sedative-Hypnotic Agents That Impact Gamma-Aminobutyric Acid Receptors: Focus on Flunitrazepam, Gamma-Hydroxybutyric Acid, Phenibut, and Selank (2021, human observational)
- Functional Connectomic Approach to Studying Selank and Semax Effects (2020, human observational)
- Antiviral properties of structural fragments of the peptide Selank (2010, human observational)
- [Immunomodulatory effects of selank in patients with anxiety-asthenic disorders] (2008, human observational)
- Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats (2022, animal)
- The Influence of Selank on the Level of Cytokines Under the Conditions of "Social" Stress (2021, animal)
- Morphological Changes in the Large Intestine of Rats Subjected to Chronic Restraint Stress and Treated with Selank (2020, animal)
- Effect of Selank on Morphological Parameters of Rat Liver in Chronic Foot-Shock Stress (2019, animal)
Conditions researched
Related compounds
- ACTH (Corticotropin)
- IGF-1 LR3
- Nootropic adjuncts (non-peptide)
- Oxytocin
- Therapeutic nicotine (patch, non-peptide)
- Vasopressin
- Angiotensin II
- BPC-157
- CRH (Corticotropin-Releasing Hormone)
- Cerebrolysin
FAQ
What is Selank?
A synthetic heptapeptide developed from tuftsin, studied mainly for anxiety; not an FDA-approved anxiety medicine.
How many registered human trials study Selank?
The PeptideWhiz trial index lists 0 registered trials for Selank.
How much published research exists on Selank?
The PeptideWhiz paper index links 3 PubMed papers to Selank; by study type, 11 human and 51 animal studies.
Which conditions is Selank researched for?
Anxiety and panic, Cognition, focus & brain performance, Fight-or-flight and nervous system overdrive.
Research and education only. Not medical advice. No dosing guidance. Data: ClinicalTrials.gov registry and PubMed via the PeptideWhiz index (204,289 studies).